Literature DB >> 9820499

B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.

P E Fields1, R J Finch, G S Gray, R Zollner, J L Thomas, K Sturmhoefel, K Lee, S Wolf, T F Gajewski, F W Fitch.   

Abstract

Using a TCR transgenic mouse bred onto a recombinase-activating gene-2-deficient background, we have examined the influence of B7.1 and B7.2 on activation of naive, CD8+ T cells in vitro. We found that B7.1 was a more potent costimulus than B7.2 for induction of proliferation and IL-2 production by naive CD8+ T cells. This difference appeared to be quantitative in nature, as determined using transfectants expressing various defined levels of B7.1 or B7.2, or using purified B7.1 or B7.2 fusion proteins. In contrast to the quantitative differences seen in stimulation of naive T cells, B7.1 and B7.2 were comparable in their ability to costimulate responses in T cells previously primed in vitro. In addition, primed, but not naive, T cells were capable of proliferating and producing IL-2 in response to a TCR stimulus alone, apparently in the absence of B7 costimulation. Lastly, we found that B7.1 and B7.2 were equivalently capable of driving differentiation of naive CD8+ T cells into an IL-4-producing phenotype when exogenous IL-4 was added to the primary culture or to an IFN-gamma-producing phenotype in the presence of IL-12. These results indicate that signals generated by B7.1 and B7.2 are qualitatively similar, but that B7.1 is quantitatively stronger than B7.2. Further, our results indicate that the activation state of the responding T cell may influence the efficiency with which the T cell can respond to a costimulatory signal provided by either B7.1 or B7.2.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820499

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

2.  Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells.

Authors:  James P O'Keefe; Kelly Blaine; Maria-Luisa Alegre; Thomas F Gajewski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

3.  B7 costimulation is critical for antibody class switching and CD8(+) cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus.

Authors:  A J McAdam; E A Farkash; B E Gewurz; A H Sharpe
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Abortive versus productive viral infection of dendritic cells with a paramyxovirus results in differential upregulation of select costimulatory molecules.

Authors:  Sharmila S Pejawar; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Immunomodulation of the anti-islet CD8 T cell response by B7-2.

Authors:  Deepak Yadav; Nora Sarvetnick
Journal:  J Clin Immunol       Date:  2007-01-23       Impact factor: 8.317

6.  Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.

Authors:  Jeffrey S Pufnock; Melinda Cigal; Lisa S Rolczynski; Erica Andersen-Nissen; Mathias Wolfl; M Juliana McElrath; Philip D Greenberg
Journal:  Blood       Date:  2011-04-14       Impact factor: 22.113

Review 7.  The future of interleukin-2: enhancing therapeutic anticancer vaccines.

Authors:  W W Overwijk; M R Theoret; N P Restifo
Journal:  Cancer J Sci Am       Date:  2000-02

8.  Toxoplasma gondii induces B7-2 expression through activation of JNK signal transduction.

Authors:  Pedro Morgado; Yi-Ching Ong; John C Boothroyd; Melissa B Lodoen
Journal:  Infect Immun       Date:  2011-09-12       Impact factor: 3.441

9.  Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells.

Authors:  Shahram Salek-Ardakani; Ramon Arens; Rachel Flynn; Alessandro Sette; Stephen P Schoenberger; Michael Croft
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  A simian virus 5 (SV5) P/V mutant is less cytopathic than wild-type SV5 in human dendritic cells and is a more effective activator of dendritic cell maturation and function.

Authors:  Subhashini Arimilli; Martha A Alexander-Miller; Griffith D Parks
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.